バイオコンバージェンスの世界市場レポート 2025年

バイオコンバージェンスの市場規模は今後数年で急成長が見込まれます。2029年にはCAGR11.1％で2,435億3,000万米ドルに成長します。予測期間の成長は、再生医療用途の拡大、慢性疾患の有病率の上昇、バイオエレクトロニクスとバイオセンサーの採用拡大、人工生体材料の開発、バイオテクノロジー研究開発への投資の急増に起因すると考えられます。主な動向としては、創薬における人工知能の統合、ラボオンチップ技術の進歩、ウェアラブルバイオセンサーの成長、3Dバイオプリンティング用途の拡大、標的治療へのナノロボティクスの利用、臓器オンチップモデルの採用、遺伝子編集技術の進歩などが挙げられます。

個別化医療が重視されるようになったことで、バイオコンバージェンス市場の成長が加速すると予想されます。個別化医療は、治療結果を最適化し、治療を強化するために、個々の患者の遺伝的、環境的、ライフスタイル的要因に基づいて治療をカスタマイズすることを含みます。ゲノム技術の進歩により、遺伝子変異をより正確に特定できるようになり、個人に合わせた治療が可能になるため、個別化医療の需要が高まっています。バイオコンバージェンスは、最先端技術と生物学的研究を統合することで個別化医療をサポートし、患者の遺伝的・分子的プロファイルに基づいた、より正確で個別化された治療計画を可能にします。このアプローチは、標的治療を容易にし、副作用を最小限に抑えることで、ヘルスケアの成果を向上させます。例えば、2024年2月、米国の非営利団体である個別化医療連合（PMC）は、米国食品医薬品局（FDA）が2023年に26の個別化新薬を承認したと報告しました。その結果、個別化医療への注目の高まりがバイオコンバージェンス市場の拡大を後押ししています。

バイオコンバージェンス市場の主要企業は、自動小型化シングルセルプロテオミクスサンプル調製などの革新的な製品の開発に注力しており、精密なタンパク質分析を可能にし、サンプルロスを最小限に抑え、シングルセル研究のワークフローを合理化しています。自動小型化シングルセルプロテオミクスサンプル調製は、超微量で個々の細胞からのタンパク質の取り扱いと調製を自動化するプロセスです。例えば、2022年9月、ドイツに本拠を置くバイオテクノロジー企業であるScienion GmbHは、質量分析ベースのシングルセルプロテオミクス分析のための再現性の高い小型化されたワークフローを促進するProteochip LF 48を発表しました。この先進的なバイオコンバージェンスツールは、個々の細胞のオンチップ溶解とタンパク質消化を可能にし、研究者がサンプルのロスを減らし、ワークフローを簡素化し、効率的な質量分析によってより深い生物学的洞察を得られるよう支援します。Proteochip LF 48は適応性が高く、正確な細胞ハンドリングとオンチップライシスおよびタンパク質消化を組み合わせることで、幅広いシングルセルプロテオミクスアプリケーションに効果的なサンプル調製を提供し、最終的にワークフローの効率とデータの質を高めます。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、貿易戦争と関税、そしてコロナ禍と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界のバイオコンバージェンスのPESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界のバイオコンバージェンス市場：成長率分析
• 世界のバイオコンバージェンス市場の実績：規模と成長、2019～2024年
• 世界のバイオコンバージェンス市場の予測：規模と成長、2024～2029年、2034年
• 世界のバイオコンバージェンス総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界のバイオコンバージェンス市場：コンポーネント別、実績と予測、2019～2024年、2024～2029年、2034年
• デバイス
• ソフトウェア
• サービス
• プラットフォーム
• 世界のバイオコンバージェンス市場：技術別、実績と予測、2019～2024年、2024～2029年、2034年
• 人工知能
• ロボット工学
• 3Dプリンティング
• ナノテクノロジー
• 合成生物学
• バイオインフォマティクス
• ウェアラブルデバイス
• 世界のバイオコンバージェンス市場：用途別、実績と予測、2019～2024年、2024～2029年、2034年
• 創薬
• 再生医療
• オプトジェネティクス
• 創薬のためのナノロボティクス
• 診断および生物学的センサー
• バイオエレクトロニクス
• 精密医療
• 世界のバイオコンバージェンス市場：エンドユーザー別、実績と予測、2019～2024年、2024～2029年、2034年
• 製薬・バイオテクノロジー業界
• 契約研究機関
• その他
• 世界のバイオコンバージェンス市場：デバイスのサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 診断装置
• 治療機器
• ウェアラブル医療機器
• 埋め込み型デバイス
• ロボット手術システム
• 世界のバイオコンバージェンス市場：ソフトウェアのサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• バイオインフォマティクスソフトウェア
• 臨床意思決定支援システム
• ゲノムデータ分析ツール
• 画像診断ソフトウェア
• 検査情報管理システム（LIMS）
• 世界のバイオコンバージェンス市場：サービスのサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 契約研究サービス
• コンサルティングおよび統合サービス
• データ管理および分析サービス
• カスタムソフトウェア開発
• 規制およびコンプライアンスサービス
• 世界のバイオコンバージェンス市場：プラットフォームのサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 人工知能プラットフォーム
• オミクス統合プラットフォーム
• デジタルヘルスプラットフォーム
• 個別化医療プラットフォーム
• クラウドベースの分析プラットフォーム

第7章 地域別・国別分析

• 世界のバイオコンバージェンス市場：地域別、実績と予測、2019～2024年、2024～2029年、2034年
• 世界のバイオコンバージェンス市場：国別、実績と予測、2019～2024年、2024～2029年、2034年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• バイオコンバージェンス市場：競合情勢
• バイオコンバージェンス市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
  • Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Veolia Environnement S.A Overview, Products and Services, Strategy and Financial Analysis
  • Novartis AG Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Eli Lilly and Company
• Amgen Inc.
• HDR Inc.
• Ginkgo Bioworks
• BICO Group AB
• MeMed Diagnostics Ltd.
• Anima Biotech
• Singota Solutions LLC
• SetPoint Medical Corporation
• Galvani Bioelectronics
• Ezassi Inc.
• Tissue Dynamics Ltd.
• Sanara Ventures Ltd.
• BioConvergent Health LLC
• Gradiant Bioconvergence Center

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• バイオコンバージェンス市場2029年：新たな機会を提供する国
• バイオコンバージェンス市場2029年：新たな機会を提供するセグメント
• バイオコンバージェンス市場2029年：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Bioconvergence is the integration of biology with engineering, data science, and advanced technologies to drive innovation in healthcare, biotechnology, and life sciences. The main objective of bioconvergence is to develop smarter, more personalized, and more efficient solutions such as precision medicine, advanced diagnostics, and bioengineered products. It enables the creation of faster, more cost-effective, and more impactful therapies, devices, and platforms.

The primary components of bioconvergence include devices, software, services, and platforms. Devices refer to hardware or tools that interact with biological systems, combining biology, engineering, and digital technology. This integration involves various advanced technologies such as artificial intelligence, robotics, 3D printing, nanotechnology, synthetic biology, bioinformatics, and wearable devices. These technologies support a wide range of applications, including drug discovery, regenerative medicine, optogenetics, nanorobotics for targeted therapies, diagnostic and biosensing tools, bioelectronics, and precision medicine. Key end users of these innovations include pharmaceutical and biotechnology companies, contract research organizations, and other stakeholders in the healthcare and life sciences industries.

The bioconvergence market research report is one of a series of new reports from The Business Research Company that provides bioconvergence market statistics, including bioconvergence industry global market size, regional shares, competitors with a bioconvergence market share, detailed bioconvergence market segments, market trends and opportunities, and any further data you may need to thrive in the bioconvergence industry. This bioconvergence market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The bioconvergence market size has grown rapidly in recent years. It will grow from $143.20 billion in 2024 to $159.66 billion in 2025 at a compound annual growth rate (CAGR) of 11.5%. The growth during the historic period can be attributed to the rise of personalized medicine, advancements in biomedical engineering, increasing healthcare digitization, the development of bioinformatics, and the collaboration between technology and biotechnology industries.

The bioconvergence market size is expected to see rapid growth in the next few years. It will grow to $243.53 billion in 2029 at a compound annual growth rate (CAGR) of 11.1%. The growth in the forecast period can be attributed to the expansion of regenerative medicine applications, rising prevalence of chronic diseases, increased adoption of bioelectronics and biosensors, development of engineered living materials, and a surge in investment in biotechnology research and development. Major trends include the integration of artificial intelligence in drug discovery, advancements in lab-on-a-chip technologies, the growth of wearable biosensors, the expansion of 3D bioprinting applications, the use of nanorobotics for targeted therapies, the adoption of organ-on-a-chip models, and progress in gene editing techniques.

The increasing emphasis on personalized medicine is expected to accelerate the growth of the bioconvergence market. Personalized medicine involves customizing treatments for individual patients based on their genetic, environmental, and lifestyle factors to optimize outcomes and enhance care. The demand for personalized medicine is rising as genomic technologies advance, allowing for more accurate identification of genetic variations and enabling tailored treatments for individuals. Bioconvergence supports personalized medicine by integrating cutting-edge technologies with biological research, allowing for more precise, individualized treatment plans based on a patient's genetic and molecular profile. This approach improves healthcare outcomes by facilitating targeted therapies and minimizing adverse effects. For example, in February 2024, the Personalized Medicine Coalition (PMC), a U.S.-based nonprofit organization, reported that the U.S. Food and Drug Administration (FDA) approved 26 new personalized medicines in 2023, marking a significant increase from the 12 approved in 2022. Consequently, the growing focus on personalized medicine is driving the bioconvergence market's expansion.

Leading companies in the bioconvergence market are focusing on the development of innovative products, such as automated miniaturized single-cell proteomics sample preparation, to enable precise protein analysis, minimize sample loss, and streamline workflows in single-cell research. Automated miniaturized single-cell proteomics sample preparation is a process that automates the handling and preparation of proteins from individual cells in ultra-low volumes. For instance, in September 2022, Scienion GmbH, a biotechnology company based in Germany, introduced the Proteochip LF 48, which facilitates reproducible and miniaturized workflows for mass spectrometry-based single-cell proteomics analysis. This advanced bioconvergence tool enables on-chip lysis and protein digestion of individual cells, helping researchers reduce sample loss, simplify workflows, and gain deeper biological insights through efficient mass spectrometry analysis. The Proteochip LF 48 is highly adaptable, offering effective sample preparation for a wide range of single-cell proteomics applications by combining precise cell handling with on-chip lysis and protein digestion, ultimately enhancing workflow efficiency and data quality.

In May 2022, BICO Group AB, a biotechnology company based in Sweden, acquired Allegro 3D Inc. for an undisclosed amount. This acquisition strengthens BICO's bioconvergence portfolio by integrating Allegro 3D's digital light processing (DLP) technology, which enables high-speed, precise bioprinting for regenerative medicine and drug testing, while also supporting scalable, animal-free tissue development. Allegro 3D Inc., based in the U.S., specializes in DLP bioprinting technology and contributes to bioconvergence through its high-precision tissue engineering and drug testing solutions.

Major players in the bioconvergence market are Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., Veolia Environnement S.A, Novartis AG, Eli Lilly and Company, Amgen Inc., HDR Inc., Ginkgo Bioworks, BICO Group AB, MeMed Diagnostics Ltd., Anima Biotech, Singota Solutions LLC, SetPoint Medical Corporation, Galvani Bioelectronics, Ezassi Inc., Tissue Dynamics Ltd., Sanara Ventures Ltd., BioConvergent Health LLC, Gradiant Bioconvergence Center.

North America was the largest region in the bioconvergence market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the Bioconvergence market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The bioconvergence market consists of revenues earned by entities by providing services such as personalized medicine development, biomedical data analysis, bioinformatics platforms, regenerative medicine solutions, diagnostic technology integration, and smart medical device engineering. The market value includes the value of related goods sold by the service provider or included within the service offering. The bioconvergence market also includes sales of bioprinted tissues and organs, lab-on-a-chip devices, smart implants, bioengineered materials, and integrated diagnostic tools. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Bioconvergence Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on bioconvergence market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for bioconvergence ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The bioconvergence market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Component: Devices; Software; Services; Platforms
• 2) By Technology: Artificial Intelligence; Robotics; Three-Dimensional (3D) Printing; Nanotechnology; Synthetic Biology; Bioinformatics; Wearable Devices
• 3) By Application: Drug Discovery; Regenerative Medicine; Optogenetics; Nanorobotics For Drug Discovery; Diagnostic And Biological Sensors; Bioelectronics; Precision Medicine
• 4) By End-User: Pharmaceutical And Biotechnology Industry; Contract Research Organization; Other End Users
• Subsegments:
• 1) By Devices: Diagnostic Devices; Therapeutic Devices; Wearable Medical Devices; Implantable Devices; Robotic Surgical Systems
• 2) By Software: Bioinformatics Software; Clinical Decision Support Systems; Genomic Data Analysis Tools; Imaging And Diagnostic Software; Laboratory Information Management Systems (LIMS)
• 3) By Services: Contract Research Services; Consulting And Integration Services; Data Management And Analysis Services; Custom Software Development; Regulatory And Compliance Services
• 4) By Platforms: Artificial Intelligence Platforms; Omics Integration Platforms; Digital Health Platforms; Personalized Medicine Platforms; Cloud-Based Analytics Platforms
• Companies Mentioned: Pfizer Inc.; Johnson & Johnson; Merck & Co. Inc.; Veolia Environnement S.A; Novartis AG
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Bioconvergence Market Characteristics

3. Bioconvergence Market Trends And Strategies

4. Bioconvergence Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Bioconvergence Growth Analysis And Strategic Analysis Framework

• 5.1. Global Bioconvergence PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Bioconvergence Market Growth Rate Analysis
• 5.4. Global Bioconvergence Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Bioconvergence Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Bioconvergence Total Addressable Market (TAM)

6. Bioconvergence Market Segmentation

• 6.1. Global Bioconvergence Market, Segmentation By Component, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Devices
• Software
• Services
• Platforms
• 6.2. Global Bioconvergence Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Artificial Intelligence
• Robotics
• Three-Dimensional (3D) Printing
• Nanotechnology
• Synthetic Biology
• Bioinformatics
• Wearable Devices
• 6.3. Global Bioconvergence Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Drug Discovery
• Regenerative Medicine
• Optogenetics
• Nanorobotics For Drug Discovery
• Diagnostic And Biological Sensors
• Bioelectronics
• Precision Medicine
• 6.4. Global Bioconvergence Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Pharmaceutical And Biotechnology Industry
• Contract Research Organization
• Other End Users
• 6.5. Global Bioconvergence Market, Sub-Segmentation Of Devices, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Diagnostic Devices
• Therapeutic Devices
• Wearable Medical Devices
• Implantable Devices
• Robotic Surgical Systems
• 6.6. Global Bioconvergence Market, Sub-Segmentation Of Software, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Bioinformatics Software
• Clinical Decision Support Systems
• Genomic Data Analysis Tools
• Imaging and Diagnostic Software
• Laboratory Information Management Systems (LIMS)
• 6.7. Global Bioconvergence Market, Sub-Segmentation Of Services, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Contract Research Services
• Consulting and Integration Services
• Data Management and Analysis Services
• Custom Software Development
• Regulatory and Compliance Services
• 6.8. Global Bioconvergence Market, Sub-Segmentation Of Platforms, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Artificial Intelligence Platforms
• Omics Integration Platforms
• Digital Health Platforms
• Personalized Medicine Platforms
• Cloud-Based Analytics Platforms

7. Bioconvergence Market Regional And Country Analysis

• 7.1. Global Bioconvergence Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Bioconvergence Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Bioconvergence Market

• 8.1. Asia-Pacific Bioconvergence Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Bioconvergence Market, Segmentation By Component, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Bioconvergence Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Bioconvergence Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Bioconvergence Market

• 9.1. China Bioconvergence Market Overview
• 9.2. China Bioconvergence Market, Segmentation By Component, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Bioconvergence Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Bioconvergence Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Bioconvergence Market

• 10.1. India Bioconvergence Market, Segmentation By Component, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Bioconvergence Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Bioconvergence Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Bioconvergence Market

• 11.1. Japan Bioconvergence Market Overview
• 11.2. Japan Bioconvergence Market, Segmentation By Component, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Bioconvergence Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Bioconvergence Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Bioconvergence Market

• 12.1. Australia Bioconvergence Market, Segmentation By Component, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Bioconvergence Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Bioconvergence Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Bioconvergence Market

• 13.1. Indonesia Bioconvergence Market, Segmentation By Component, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Bioconvergence Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Bioconvergence Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Bioconvergence Market

• 14.1. South Korea Bioconvergence Market Overview
• 14.2. South Korea Bioconvergence Market, Segmentation By Component, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Bioconvergence Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Bioconvergence Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Bioconvergence Market

• 15.1. Western Europe Bioconvergence Market Overview
• 15.2. Western Europe Bioconvergence Market, Segmentation By Component, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Bioconvergence Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Bioconvergence Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Bioconvergence Market

• 16.1. UK Bioconvergence Market, Segmentation By Component, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Bioconvergence Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Bioconvergence Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Bioconvergence Market

• 17.1. Germany Bioconvergence Market, Segmentation By Component, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Bioconvergence Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Bioconvergence Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Bioconvergence Market

• 18.1. France Bioconvergence Market, Segmentation By Component, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Bioconvergence Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Bioconvergence Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Bioconvergence Market

• 19.1. Italy Bioconvergence Market, Segmentation By Component, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Bioconvergence Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Bioconvergence Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Bioconvergence Market

• 20.1. Spain Bioconvergence Market, Segmentation By Component, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Bioconvergence Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Bioconvergence Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Bioconvergence Market

• 21.1. Eastern Europe Bioconvergence Market Overview
• 21.2. Eastern Europe Bioconvergence Market, Segmentation By Component, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Bioconvergence Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Bioconvergence Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Bioconvergence Market

• 22.1. Russia Bioconvergence Market, Segmentation By Component, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Bioconvergence Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Bioconvergence Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Bioconvergence Market

• 23.1. North America Bioconvergence Market Overview
• 23.2. North America Bioconvergence Market, Segmentation By Component, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Bioconvergence Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Bioconvergence Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Bioconvergence Market

• 24.1. USA Bioconvergence Market Overview
• 24.2. USA Bioconvergence Market, Segmentation By Component, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Bioconvergence Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Bioconvergence Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Bioconvergence Market

• 25.1. Canada Bioconvergence Market Overview
• 25.2. Canada Bioconvergence Market, Segmentation By Component, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Bioconvergence Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Bioconvergence Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Bioconvergence Market

• 26.1. South America Bioconvergence Market Overview
• 26.2. South America Bioconvergence Market, Segmentation By Component, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Bioconvergence Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Bioconvergence Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Bioconvergence Market

• 27.1. Brazil Bioconvergence Market, Segmentation By Component, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Bioconvergence Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Bioconvergence Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Bioconvergence Market

• 28.1. Middle East Bioconvergence Market Overview
• 28.2. Middle East Bioconvergence Market, Segmentation By Component, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Bioconvergence Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Bioconvergence Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Bioconvergence Market

• 29.1. Africa Bioconvergence Market Overview
• 29.2. Africa Bioconvergence Market, Segmentation By Component, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Bioconvergence Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Bioconvergence Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Bioconvergence Market Competitive Landscape And Company Profiles

• 30.1. Bioconvergence Market Competitive Landscape
• 30.2. Bioconvergence Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Veolia Environnement S.A Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Novartis AG Overview, Products and Services, Strategy and Financial Analysis

31. Bioconvergence Market Other Major And Innovative Companies

• 31.1. Eli Lilly and Company
• 31.2. Amgen Inc.
• 31.3. HDR Inc.
• 31.4. Ginkgo Bioworks
• 31.5. BICO Group AB
• 31.6. MeMed Diagnostics Ltd.
• 31.7. Anima Biotech
• 31.8. Singota Solutions LLC
• 31.9. SetPoint Medical Corporation
• 31.10. Galvani Bioelectronics
• 31.11. Ezassi Inc.
• 31.12. Tissue Dynamics Ltd.
• 31.13. Sanara Ventures Ltd.
• 31.14. BioConvergent Health LLC
• 31.15. Gradiant Bioconvergence Center

32. Global Bioconvergence Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Bioconvergence Market

34. Recent Developments In The Bioconvergence Market

35. Bioconvergence Market High Potential Countries, Segments and Strategies

• 35.1 Bioconvergence Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Bioconvergence Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Bioconvergence Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer